Identification of ALK, ROS1, and RET Fusions by a Multiplexed mRNA-Based Assay in Formalin-Fixed, Paraffin-Embedded Samples from Advanced Non–Small-Cell Lung Cancer Patients | Zendy

Noemı́ Reguart | Zendy; Cristina Teixidó | Zendy; Ana GiménezCapitán | Zendy; Laia Paré | Zendy; Patricia Galván | Zendy; Santiago Viteri | Zendy; Sónia Rodríguez | Zendy; Vicente Peg | Zendy; Erika Aldeguer | Zendy; Núria Viñolas | Zendy; Jordi Remón | Zendy; Niki Karachaliou | Zendy; Esther Conde | Zendy; Fernando López-Rı́os | Zendy; Ernest Nadal | Zendy; Sabine MerkelbachBruse | Zendy; Reinhard Büttner | Zendy; Rafael Rosell | Zendy; Miguel Ángel MolinaVila | Zendy; Aleix Prat | Zendy

Open Access

Identification of ALK, ROS1, and RET Fusions by a Multiplexed mRNA-Based Assay in Formalin-Fixed, Paraffin-Embedded Samples from Advanced Non–Small-Cell Lung Cancer Patients

Author(s) -

Noemı́ Reguart,

Cristina Teixidó,

Ana GiménezCapitán,

Laia Paré,

Patricia Galván,

Santiago Viteri,

Sónia Rodríguez,

Vicente Peg,

Erika Aldeguer,

Núria Viñolas,

Jordi Remón,

Niki Karachaliou,

Esther Conde,

Fernando López-Rı́os,

Ernest Nadal,

Sabine MerkelbachBruse,

Reinhard Büttner,

Rafael Rosell,

Miguel Ángel MolinaVila,

Aleix Prat

Publication year - 2017

Publication title -

clinical chemistry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.705

H-Index - 218

eISSN - 1530-8561

pISSN - 0009-9147

DOI - 10.1373/clinchem.2016.265314

Subject(s) - ros1 , anaplastic lymphoma kinase , lung cancer , immunohistochemistry , crizotinib , fusion gene , cancer research , tyrosine kinase , medicine , concordance , cancer , tissue microarray , oncogene , taqman , pathology , oncology , biology , real time polymerase chain reaction , receptor , gene , adenocarcinoma , biochemistry , cell cycle , malignant pleural effusion

Anaplastic lymphoma receptor tyrosine kinase ( ALK ), ROS proto-oncogene 1, receptor tyrosine kinase ( ROS1 ), and ret proto-oncogene ( RET ) fusions are present in 5%-7% of patients with advanced non-small-cell lung cancer (NSCLC); their accurate identification is critical to guide targeted therapies. FISH and immunohistochemistry (IHC) are considered the gold standards to determine gene fusions, but they have limitations. The nCounter platform is a potentially useful genomic tool for multiplexed detection of gene fusions, but has not been validated in the clinical setting.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research